Transcription factors that play a central role in the mechanism of action of drugs have been identified using ChIP-Atlas.

A paper has been published using a database supported by JST-NBDC Database Integration Coordination Program (DICP).

Shinya Oki, Associate Professor of Kyoto University, and Yoshihiro Yamanishi, Professor of Kyushu Institute of Technology, et al., have succeeded in identifying transcription factors that play central roles in the mechanisms of action (MoA) of drugs using "ChIP-Atlas".
The result of this research has been published in a scientific journal "BMC Bioinformatics" on January 25, 2022 (UK time).

Expression of many genes change with drug administration, but its molecular mechanism has not been elucidated.
They predicted that, (1) cisplatin promotes the anti-tumor activity of TP53 family members but suppresses the cancer-inducing function of MYCs; (2) inhibition of RELA and E2F1 is pivotal for leflunomide to exhibit antiproliferative activity; and (3) CHD8 mediates valproic acid-induced autism.

It is expected that elucidating the mechanism of action of drugs centered on transcription factors would lead to development of new therapeutic methods for diseases, discovery of new drugs, discovery of target molecules, construction of hypothesis of new application of existing drugs and side effect risk. Through this study, it has been shown that ChIP-Atlas would be a useful tool for building hypothesis in data-driven research from an epigenetic point of view.

"ChIP-Atlas" is an integrated database in epigenomics which contains almost all data from public database of ChIP-seq, ATAC-seq, DNase-seq and Bisulfite-seq re-analyzed by unified protocols, respectively, and organized by antigen, species and cell types.